- Home
- BZUN vs IMUX Comparison
BZUN vs IMUX Comparison
Compare BZUN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- IMUX
- Stock Information
- Founded
- BZUN 2007
- IMUX 2016
- Country
- BZUN China
- IMUX United States
- Employees
- BZUN N/A
- IMUX N/A
- Industry
- BZUN Catalog/Specialty Distribution
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- IMUX Health Care
- Exchange
- BZUN Nasdaq
- IMUX Nasdaq
- Market Cap
- BZUN 131.7M
- IMUX 107.3M
- IPO Year
- BZUN N/A
- IMUX N/A
- Fundamental
- Price
- BZUN $2.85
- IMUX $0.66
- Analyst Decision
- BZUN Buy
- IMUX Strong Buy
- Analyst Count
- BZUN 2
- IMUX 6
- Target Price
- BZUN $3.20
- IMUX $11.60
- AVG Volume (30 Days)
- BZUN 428.9K
- IMUX 1.4M
- Earning Date
- BZUN 05-21-2025
- IMUX 05-15-2025
- Dividend Yield
- BZUN N/A
- IMUX N/A
- EPS Growth
- BZUN N/A
- IMUX N/A
- EPS
- BZUN N/A
- IMUX N/A
- Revenue
- BZUN $1,310,110,798.00
- IMUX N/A
- Revenue This Year
- BZUN $5.14
- IMUX N/A
- Revenue Next Year
- BZUN $4.04
- IMUX N/A
- P/E Ratio
- BZUN N/A
- IMUX N/A
- Revenue Growth
- BZUN 6.77
- IMUX N/A
- 52 Week Low
- BZUN $2.11
- IMUX $0.56
- 52 Week High
- BZUN $4.38
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- BZUN 43.87
- IMUX 26.54
- Support Level
- BZUN $2.90
- IMUX $0.56
- Resistance Level
- BZUN $3.06
- IMUX $0.95
- Average True Range (ATR)
- BZUN 0.18
- IMUX 0.08
- MACD
- BZUN -0.07
- IMUX -0.03
- Stochastic Oscillator
- BZUN 3.23
- IMUX 20.22
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.